Target intelligence / Profile preview

MicroRNA 103b-2 (MIR103B2)

Target
MIR103B2
Molecular classification
microRNA, Non-coding RNA
01

Overview

MicroRNA 103b-2 is a small, single-stranded non-coding RNA molecule found in humans and other animals. Like other microRNAs, it regulates gene expression by binding to complementary sequences in target mRNAs, leading to mRNA degradation or suppression of translation. Its functions are inferred from broader miRNA research, including involvement in cellular homeostasis, development, and disease processes, especially oncogenesis. Direct functional annotation for MIR103B2 is scarce, but its classification is well established as an miRNA gene locus. Structurally and functionally, MIR103B2 shares conserved features with other miR-103 family members, but detailed, target-specific interactions and disease associations require further study. If studied directly, its function would be assessed in the context of gene regulatory networks relevant to human health and disease.

Other names
hsa-mir-103-2-ashsa-mir-103b-2MIR103-2-ASMIR103-2ASMIRN103-2ASmicroRNA 103-2-as
02

Mechanism of action

Not applicable for drugs, but as a miRNA, its biological mechanism is RNA silencing via base pairing with target mRNAs leading to mRNA degradation or translation inhibition

03

Biological functions

Post-transcriptional gene silencingRegulation of mRNA stabilityModulation of protein translationPossible involvement in cell cycle, apoptosis, and differentiation, as these are common miRNA functions
04

Disease associations

Potentially implicated in cancer (many miRNAs are associated with oncogenic or tumor suppressive activities)Other disease roles are not well characterized for MIR103B2 specifically; miR-103 family members have been linked to metabolic disease, neurological disorders, and cardiovascular function, but direct evidence for MIR103B2 is sparse
05

Safety considerations

Therapeutic targeting of miRNAs can induce off-target effects and alter the regulation of multiple genes, raising concerns for specificity and systemic impact; specific risks for MIR103B2-based interventions are not documented.
06

Interacting drugs

None specifically known; no direct-targeting pharmaceutical agents are documented for MIR103B2
07

Biomarkers

miRNAs, including MIR103B2, are emerging as biomarkers in various contexts such as cancer or metabolic disease diagnosis/prognosis, but MIR103B2-specific data on clinical biomarker use is limited

Beyond the preview

Go deeper on MicroRNA 103b-2 (MIR103B2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 103b-2 (MIR103B2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call